NOACS治疗房颤合并急性冠脉综合征的研究

Study of NOACS in the Treatment of Atrial Fibrillation Complicated with Acute Coronary Syndrome

心房颤动合并急性冠脉综合征的发病率逐年增高,其治疗方案越来越受到人们的关注。由于冠脉血栓和房颤血栓的形成机制不同,因此抗栓治疗的难点在于如何平衡出血和血栓风险,以减少并发症的发生。近年来,新型口服抗凝药物的上市为抗栓治疗提供了新的思路,本文将对新型口服抗凝药物在房颤合并急性冠脉综合征患者抗栓治疗方面的相关研究进行综述。

The incidence of atrial fibrillation complicated with acute coronary syndrome has increased year by year, and its treatment plan has attracted more and more attention. Because of the different mechanisms of coronary thrombosis and atrial fibrillation, the difficulty in antithrombotic therapy is how to balance the risk of bleeding and thrombosis to reduce the incidence of complications. In recent years, the launch of new oral anticoagulant drugs has provided new ideas for antithrombotic therapy. This article will review the related research on new oral anticoagulant drugs in the treatment of atrial fibrillation with antithrombotic therapy in patients with acute coronary syndrome.